Next-generation drug delivery systems for aspergillosis: Overcoming barriers in antifungal therapy

Area of Science:

• Medical Mycology
• Pharmaceutics
• Drug Delivery Systems

Background:

• Aspergillosis, caused by Aspergillus fumigatus, is a critical global health concern impacting morbidity and mortality.
• The respiratory system is the primary site for aspergillosis, presenting as allergic reactions or invasive disease.
• Current treatments for invasive aspergillosis have limitations, including poor bioavailability, toxicity, and emerging antifungal resistance.

Purpose of the Study:

• To review recent advancements in drug delivery technologies for treating aspergillosis.
• To highlight strategies for overcoming limitations of conventional antifungal therapies.
• To explore innovative approaches for improving outcomes in both allergic and invasive aspergillosis.

Main Methods:

• Review of recent literature on particulate drug delivery systems for pulmonary administration.
• Analysis of various platforms including microparticles, nanoparticles, micelles, and lipid-based carriers.
• Examination of antifungals like itraconazole, voriconazole, and amphotericin B incorporated into these systems.

Main Results:

• Development of innovative particulate delivery systems (microparticles, nanoparticles, micelles, lipid carriers) for enhanced pulmonary delivery of antifungals.
• These systems aim to improve drug targeting, prolong release, reduce systemic exposure, and minimize side effects.
• Preclinical evidence supports the potential of aerosolized antifungal therapy via nebulizers or dry powder inhalers (DPIs).

Conclusions:

• Advanced drug delivery systems show promise in overcoming limitations of current aspergillosis treatments.
• Pulmonary delivery of antifungals using novel carriers could significantly improve therapeutic outcomes.
• Further research into inhalation-based treatments is crucial for reshaping the future management of aspergillosis.